Moreover, Cader et al. identified a new CD3−/CD68+/CD4+/GrB+ subset that was associated with the response to PD-1 inhibitors in the blood and tissue ME of cHL patients; these cells may represent a monocyte population that utilize granzyme B to destroy antibody-coated targets via antibody-dependent cellular cytotoxicity [132]. Here, CD68 is linked to classic Hodgkin lymphoma.